|
|
Volumn 9, Issue 1, 2015, Pages 25-34
|
|
Complementary versus companion diagnostics: Apples and oranges?
a
|
|
Author keywords
Companion diagnostics; complementary diagnostics; late stage pipeline analysis; partnering landscape; personalized medicine
|
|
Indexed keywords
BIOLOGICAL MARKER;
BITOPERTIN;
BRENTUXIMAB VEDOTIN;
GLYCINE TRANSPORTER 1;
IBRUTINIB;
MASITINIB;
NELIPEPIMUT S;
ONARTUZUMAB;
PROTEIN TYROSINE KINASE INHIBITOR;
VERCIRNON;
ASTHMA;
AUTOIMMUNE DISEASE;
BREAST CANCER;
CANCER IMMUNIZATION;
CHRONIC LYMPHATIC LEUKEMIA;
CLINICAL TRIAL (TOPIC);
COMMERCIAL PHENOMENA;
COMPANION DIAGNOSTIC;
COMPLEMENTARY DIAGNOSTIC;
COST EFFECTIVENESS ANALYSIS;
CROHN DISEASE;
DIAGNOSTIC EQUIPMENT;
DIAGNOSTIC TEST;
DIGESTIVE SYSTEM CANCER;
DRUG APPROVAL;
DRUG EFFICACY;
DRUG INDUSTRY;
DRUG INFORMATION;
DRUG MARKETING;
DRUG RESPONSE;
DRUG TARGETING;
HEALTH CARE SYSTEM;
HUMAN;
LYMPHOMA;
MASTOCYTOSIS;
NEUROLOGIC DISEASE;
NEXT GENERATION SEQUENCING;
PERSONALIZED MEDICINE;
REIMBURSEMENT;
REVIEW;
RHEUMATOID ARTHRITIS;
SCHIZOPHRENIA;
VALIDITY;
AUTOIMMUNE DISEASES;
DIFFERENTIAL DIAGNOSIS;
ECONOMICS;
METABOLISM;
NEOPLASMS;
AUTOIMMUNE DISEASES;
BIOLOGICAL MARKERS;
DIAGNOSIS, DIFFERENTIAL;
HUMANS;
INDIVIDUALIZED MEDICINE;
NEOPLASMS;
|
|
EID: 84921633638
PISSN: 17520363
EISSN: 17520371
Source Type: Journal
DOI: 10.2217/bmm.14.84 Document Type: Review |
|
Times cited : (31)
|
|
References (22)
|
